Richard Smith

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study. Ella Zomer, BBiomedSc, PhD, senior research fellow at Monash University School of Public Health and Preventive Medicine in Melbourne, Australia, and colleagues estimated that the cost of semaglutide 2.4 mg

Postmenopausal women with a history of hormone therapy use were biologically younger compared with never-using counterparts, regardless of socioeconomic background, according to study results published in JAMA Network Open.“Among the factors involved in women’s health, hormone therapy (HT) has been the focus of much attention. Menopause is associated with the loss of estrogen

Key takeaways: Many women report cannabis use to manage menopause symptoms, despite lack of evidence-based studies.

Key takeaways: According to a Defense Health Agency report, 30.5% of Military Health System beneficiaries have obesity.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Obstetric outcomes for gestational carriers were similar to non-surrogate pregnancies using fertility treatments, with both groups having higher odds for hypertensive disorders of pregnancy vs. general pregnancies, data show.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo. The semaglutide 2.4 mg (Wegovy, Novo Nordisk) group also had lower rates of all-cause death and non-CV death compared with the placebo group, according to the findings presented at the European

The decline in maternal deaths after the Dobbs decision was likely affected by a spike in COVID-19-related deaths during 2021, complicating efforts to assess the ramifications of restrictions on abortion access, researchers reported.

Canyon View isn't abandoning its Air Raid offense and 300-pound linemen did not suddensly sprout from the soil of Waddell.

The timing of when a patient takes their blood pressure medication does not appear to matter for reducing CV event risk, according to two trials and a meta-analysis presented at the European Society of Cardiology Congress.